NDAORALTABLET
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
ZURAMPIC (lesinurad) by Ironwood Pharmaceuticals. Approved for gout. First approved in 2015.
Drug data last refreshed 19h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (2)
Post-Authorisation Safety Study of Lesinurad
Started Jan 2021
0GoutHyperuricemia
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
Started Jul 2017
242 enrolled
GoutChronic Kidney Disease (CKD)
Company
Worked on ZURAMPIC at Ironwood Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.